Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
New Directions for Treatment and Assessment of Ulcerative Colitis
share announcement

New Directions for Treatment and Assessment of Ulcerative Colitis

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".

Deadline for manuscript submissions: 25 August 2025 | Viewed by 4294

Special Issue Editors

Dr. Andrea van der Meulen

E-Mail Website
Guest Editor
Department of Gastroenterology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands
Interests: inflammatory bowel disease; perianal disease; patient stratification; personalized medicine
Special Issues, Collections and Topics in MDPI journals
Dr. Christian Selinger

E-Mail Website
Guest Editor
Leeds Gastroenterology Institute, St James University Hospital, 4th Floor Bexley Wing, Beckett Street, Leeds LS9 7TF, UK
Interests: IBD; IBD & pregnancy; real world evidence; IBD in special situations
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Treatment options and paradigms are shifting for ulcerative colitis. Recently licensed treatment options have increased the number of choices for clinicians and patients. Treatment targets are a topic of hot debate, and ultrasound assessment offers a new option of assessing ulcerative colitis. This Special Issue invites submissions addressing these new developments and guiding clinicians how to best approach these new challenges.

Dr. Andrea van der Meulen
Dr. Christian Selinger
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • treatment
  • ulcerative colitis
  • treatment target
  • ultrasound assessment
  • approach

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

16 pages, 292 KiB  
Review
The Cell-Specific Effects of JAK1 Inhibitors in Ulcerative Colitis
by Suzanne H. C. Veltkamp and Philip W. Voorneveld
J. Clin. Med. 2025, 14(2), 608; https://doi.org/10.3390/jcm14020608 - 18 Jan 2025
Cited by 1 | Viewed by 1298
Abstract
JAK1 inhibitors have become an important addition to the therapeutic options for ulcerative colitis (UC), targeting key inflammatory pathways mediated by cytokines such as the IL-6 family, interferons, IL-2 family, IL-10 family, and G-CSF. However, not all patients respond equally, and chronic inflammation [...] Read more.
JAK1 inhibitors have become an important addition to the therapeutic options for ulcerative colitis (UC), targeting key inflammatory pathways mediated by cytokines such as the IL-6 family, interferons, IL-2 family, IL-10 family, and G-CSF. However, not all patients respond equally, and chronic inflammation persists in a subset of individuals. The variability in treatment response may reflect the heterogeneity of UC. Immune cells, epithelial cells, and stromal cells may have distinct contributions to disease pathogenesis. While JAK inhibitors were originally designed to target immune cells, their impact on non-immune cell types, such as epithelial and stromal cells, remains poorly understood. Investigating the mechanisms through which JAK1 inhibitors affect these diverse cellular populations and identifying the factors underlying differential responses is crucial to optimizing outcomes. This review explores the roles of immune, epithelial, and stromal cells in response to JAK1 inhibition and discusses potential strategies to improve treatment precision, such as predicting responders and identifying complementary therapeutic targets. Full article
(This article belongs to the Special Issue New Directions for Treatment and Assessment of Ulcerative Colitis)
19 pages, 1467 KiB  
Review
Recent Advances in the Management of Acute Severe Ulcerative Colitis
by Elaine Ong Ming San, Kassem Sharif, Konstantina Rosiou, Michael Rennie and Christian Philipp Selinger
J. Clin. Med. 2024, 13(23), 7446; https://doi.org/10.3390/jcm13237446 - 6 Dec 2024
Viewed by 2637
Abstract
Acute severe ulcerative colitis is a medical emergency requiring inpatient treatment with intravenous steroids. Approximately one-third of patients do not respond to steroids sufficiently and require medical rescue therapy. Infliximab and cyclosporine are equally effective rescue agents, though infliximab is often preferred by [...] Read more.
Acute severe ulcerative colitis is a medical emergency requiring inpatient treatment with intravenous steroids. Approximately one-third of patients do not respond to steroids sufficiently and require medical rescue therapy. Infliximab and cyclosporine are equally effective rescue agents, though infliximab is often preferred by clinicians for ease of use and greater familiarity. The use of cyclosporine is becoming more frequent, however, in patients previously exposed to infliximab. Those patients not exhibiting an adequate response to rescue therapy require colectomy. There is increasing interest in modified medical treatment to rescue the need for surgery. Janus kinase inhibitors may provide benefits when used alongside steroids from admission or as a rescue agent, but further randomised trials are needed to clearly establish their role. Intensified dosing of infliximab when used as a rescue therapy has shown mixed results but seems sensible in patients with low albumin and high disease burden. In this review, we describe the current established treatment pathways and report newer developments and evolving concepts that may in the future improve the care of patients with acute severe ulcerative colitis. Full article
(This article belongs to the Special Issue New Directions for Treatment and Assessment of Ulcerative Colitis)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop